We are live on ! Find out more
KPTI icon

Karyopharm Therapeutics
KPTI

168 hedge funds and large institutions have $987M invested in Karyopharm Therapeutics in 2020 Q4 according to their latest regulatory filings, with 32 funds opening new positions, 61 increasing their positions, 44 reducing their positions, and 21 closing their positions.

New
Increased
Maintained
Reduced
Closed

52% more first-time investments, than exits

New positions opened: 32 | Existing positions closed: 21

40% more call options, than puts

Call options by funds: $11.2M | Put options by funds: $7.99M

39% more repeat investments, than reductions

Existing positions increased: 61 | Existing positions reduced: 44

7% more funds holding

Funds holding: 157 → 168 (+11)

4% more capital invested

Capital invested by funds: $949M → $987M (+$38.7M)

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

0.13% less ownership

Funds ownership: 5.91% → 5.78% (-0.13%)

Holders
168
Holders Change
+11
Holders Change %
+7.01%
% of All Funds
2.97%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.04%
New
32
Increased
61
Reduced
44
Closed
21
Calls
$11.2M
Puts
$7.99M
Net Calls
+$3.23M
Net Calls Change
+$273K

Top Buyers

Rank Fund Capital Flow
1
Millennium Management
Millennium Management
New York
+$36M
2
LCM
Laurion Capital Management
New York
+$12.8M
3
CWG
C WorldWide Group
Denmark
+$9.27M
4
State Street
State Street
Massachusetts
+$8.51M
5
Alkeon Capital Management
Alkeon Capital Management
New York
+$7.75M

Top Sellers

Rank Fund Capital Flow
1
ACA
Avoro Capital Advisors
New York
-$87.6M
2
Two Sigma Investments
Two Sigma Investments
New York
-$19.3M
3
D.E. Shaw & Co
D.E. Shaw & Co
New York
-$15.5M
4
Adage Capital Partners
Adage Capital Partners
Massachusetts
-$11.6M
5
Two Sigma Advisers
Two Sigma Advisers
New York
-$10.5M
Name Holding Trade Value Shares
Change 		Change in
Stake
AllianceBernstein
51
AllianceBernstein
Tennessee
$2.01M – – –
RhumbLine Advisers
52
RhumbLine Advisers
Massachusetts
$1.93M +$46.3K +200 +2%
Swiss National Bank
53
Swiss National Bank
Switzerland
$1.8M – – –
California State Teachers Retirement System (CalSTRS)
54
California State Teachers Retirement System (CalSTRS)
California
$1.64M – – –
IHAM
55
Integral Health Asset Management
New York
$1.55M -$1.16M -5,000 -43%
State of Wisconsin Investment Board
56
State of Wisconsin Investment Board
Wisconsin
$1.55M -$536K -2,313 -26%
BNP Paribas Financial Markets
57
BNP Paribas Financial Markets
France
$1.47M +$1.22M +5,269 +487%
Qube Research & Technologies (QRT)
58
Qube Research & Technologies (QRT)
United Kingdom
$1.41M +$910K +3,927 +182%
Group One Trading
59
Group One Trading
Illinois
$1.31M +$958K +4,136 +277%
Luther King Capital Management (LKCM)
60
Luther King Capital Management (LKCM)
Texas
$1.25M +$140K +605 +13%
New York State Common Retirement Fund
61
New York State Common Retirement Fund
New York
$1.24M – – –
Squarepoint
62
Squarepoint
New York
$1.24M -$1.21M -5,231 -49%
PPA
63
Parametric Portfolio Associates
Washington
$1.22M +$517K +2,229 +73%
MC
64
Maverick Capital
Texas
$1.16M +$1.16M +4,999 New
KOCAA
65
Knights of Columbus Asset Advisors
Connecticut
$1.13M -$2.08K -9 -0.2%
AC
66
Athanor Capital
New York
$1.11M +$1.11M +4,795 New
Man Group
67
Man Group
United Kingdom
$1.1M +$9.96K +43 +0.9%
Jane Street
68
Jane Street
New York
$1.1M -$177K -764 -14%
UBS Group
69
UBS Group
Switzerland
$1.06M -$2.08M -8,989 -66%
TCM
70
Tekla Capital Management
Massachusetts
$1.02M – – –
UBS AM
71
UBS AM
Illinois
$973K +$195K +841 +25%
JAMH
72
Junson Asset Management (HK)
Hong Kong
$953K +$951K +4,106 New
Rafferty Asset Management
73
Rafferty Asset Management
New York
$912K -$1.25M -5,386 -58%
First Trust Advisors
74
First Trust Advisors
Illinois
$888K -$410K -1,770 -32%
Russell Investments Group
75
Russell Investments Group
United Kingdom
$864K -$87.6K -378 -9%
1 2
3
4 5

KPTI Hedge Fund Activity: Q4 2020 in Review

168 of the 5,652 institutional investors tracked by Wall St. Rank reported a position in Karyopharm Therapeutics (KPTI) for Q4 2020, worth a combined $987M — up 4.1% from $949M a quarter earlier.

Buyers outnumbered sellers: 32 funds opened new KPTI positions and 21 closed out — a net gain of 11 holders — while 61 added to existing stakes and 44 trimmed.

The largest buyer was Millennium Management, adding an estimated $36M. The largest seller was Avoro Capital Advisors, exiting entirely with an estimated $87.6M sold.

  • 168 institutional investors held Karyopharm Therapeutics (KPTI) as of Q4 2020, up from 157 in Q3 2020.
  • Funds reported $987M of Karyopharm Therapeutics stock for Q4 2020, up 4.1% quarter-over-quarter.
  • 32 funds opened new Karyopharm Therapeutics positions in Q4 2020 and 21 closed out, a net change of +11 holders.
  • The largest Karyopharm Therapeutics buyer in Q4 2020 was Millennium Management, an estimated $36M added.
  • The largest Karyopharm Therapeutics seller in Q4 2020 was Avoro Capital Advisors, an estimated $87.6M sold.

Based on aggregated 13F filings for Q4 2020.